Abstract

Concomitant chemoradiation (CRT) for locally advanced cervical cancer has become an established treatment based on randomised trials. Major concerns, however, remain over the acute and late toxicity and hence the generalisability of the conclusions of these studies. The study period was from October 2020 to May 2022. A total of 126 patients with Stage IIB to IIIB Cervical Cancer were taken for the study from Patna Medical College Hospital, Patna, Bihar with consent from the patients. Most of the patients were of stage IIIB (47.60%) in group A and (54%) in group B. Most of the patients had parity ˃5 (68.30%) in group A and (87.30%) in group B. Most of the patients (58.73%) in group A and (66.66%) in group B completed EBRT within the schedule time of 35 days. Twenty seven (42.85%) patients in group A and twenty three (36.50%) patients in group B had break during EBRT due to toxicity. In conclusion, observation during follow up after 6 months group A patients 74.60% had no evidence of disease and in group B 76.19% had no evidence of disease or no residual disease. In group A 25.40% had residual disease and in group B 24.60% had residual disease.

Key words: Cervical Cancer, Concomitant chemoradiation, Uterine cervix, Cell carcinoma